123 related articles for article (PubMed ID: 36302189)
21. Small Cell Neuroendocrine Carcinoma of the Endometrium with Difficulty Identifying the Original Site in the Uterus.
Iida T; Muramatsu T; Kajiwara H; Kato N; Itoh H; Narayama T; Machida H; Ikeda M; Shida M; Hirasawa T; Mikami M
Tokai J Exp Clin Med; 2020 Dec; 45(4):156-161. PubMed ID: 33300584
[TBL] [Abstract][Full Text] [Related]
22. [Endometrial carcinomas and precursor lesions--new aspects].
Schmidt D
Pathologe; 2009 Jul; 30(4):261-7. PubMed ID: 19495762
[TBL] [Abstract][Full Text] [Related]
23. Clinicopathologic Association and Prognostic Value of Microcystic, Elongated, and Fragmented (MELF) Pattern in Endometrial Endometrioid Carcinoma.
Kihara A; Yoshida H; Watanabe R; Takahashi K; Kato T; Ino Y; Kitagawa M; Hiraoka N
Am J Surg Pathol; 2017 Jul; 41(7):896-905. PubMed ID: 28418994
[TBL] [Abstract][Full Text] [Related]
24. Expression of imatinib mesylate-targeted kinases in endometrial carcinoma.
Slomovitz BM; Broaddus RR; Schmandt R; Wu W; Oh JC; Ramondetta LM; Burke TW; Gershenson DM; Lu KH
Gynecol Oncol; 2004 Oct; 95(1):32-6. PubMed ID: 15385107
[TBL] [Abstract][Full Text] [Related]
25. Endometrial giant cell carcinoma: a case series and review of the spectrum of endometrial neoplasms containing giant cells.
Mulligan AM; Plotkin A; Rouzbahman M; Soslow RA; Gilks CB; Clarke BA
Am J Surg Pathol; 2010 Aug; 34(8):1132-8. PubMed ID: 20588176
[TBL] [Abstract][Full Text] [Related]
26. Does high-grade endometrioid carcinoma (grade 3 FIGO) belong to type I or type II endometrial cancer? A clinical-pathological and immunohistochemical study.
Zannoni GF; Vellone VG; Arena V; Prisco MG; Scambia G; Carbone A; Gallo D
Virchows Arch; 2010 Jul; 457(1):27-34. PubMed ID: 20552366
[TBL] [Abstract][Full Text] [Related]
27. CD10 and calretinin staining of endocervical glandular lesions, endocervical stroma and endometrioid adenocarcinomas of the uterine corpus: CD10 positivity is characteristic of, but not specific for, mesonephric lesions and is not specific for endometrial stroma.
McCluggage WG; Oliva E; Herrington CS; McBride H; Young RH
Histopathology; 2003 Aug; 43(2):144-50. PubMed ID: 12877729
[TBL] [Abstract][Full Text] [Related]
28. Mucinous differentiation does not impact stage or risk of recurrence among patients with grade 1, endometrioid type, endometrial carcinoma.
Worley MJ; Davis M; Berhie SH; Muto MG; Feltmate CM; Berkowitz RS; Horowitz NS; Campos SM
Gynecol Oncol; 2014 Oct; 135(1):54-7. PubMed ID: 25088333
[TBL] [Abstract][Full Text] [Related]
29. Improved Outcome of High-Grade, Early 1-Stage Endometrioid Endometrial Carcinoma With Adjuvant Chemotherapy and Radiotherapy: Comparison of 2 Treatment Strategies.
Reynaers EA; Jutzi L; Ezendam NP; Kwon JS; Pijnenborg JM
Int J Gynecol Cancer; 2017 Mar; 27(3):467-472. PubMed ID: 28129237
[TBL] [Abstract][Full Text] [Related]
30. The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma.
Zheng W; Yi X; Fadare O; Liang SX; Martel M; Schwartz PE; Jiang Z
Am J Surg Pathol; 2008 Feb; 32(2):304-15. PubMed ID: 18223334
[TBL] [Abstract][Full Text] [Related]
31. Aquaporin 3 Expression in Endometrioid Carcinoma of the Uterine Body Correlated With Early Stage and Lower Grade.
Watanabe T; Sato K; Kono T; Yamagishi Y; Kumazawa F; Miyamoto M; Takano M; Tsuda H
Pathol Oncol Res; 2020 Oct; 26(4):2247-2253. PubMed ID: 32382899
[TBL] [Abstract][Full Text] [Related]
32. Association of low-grade endometrioid carcinoma of the uterus and ovary with undifferentiated carcinoma: a new type of dedifferentiated carcinoma?
Silva EG; Deavers MT; Bodurka DC; Malpica A
Int J Gynecol Pathol; 2006 Jan; 25(1):52-8. PubMed ID: 16306785
[TBL] [Abstract][Full Text] [Related]
33. Adjuvant chemotherapy in early-stage endometrioid endometrial cancer with >50% myometrial invasion and negative lymph nodes.
Multinu F; Garzon S; Weaver AL; McGree ME; Sartori E; Landoni F; Zola P; Dinoi G; Aletti G; Block MS; Gadducci A; Mariani A
Int J Gynecol Cancer; 2021 Apr; 31(4):537-544. PubMed ID: 33608453
[TBL] [Abstract][Full Text] [Related]
34. Relationship between morular metaplasia and squamous differentiation in endometrial carcinoma.
Travaglino A; Raffone A; Gencarelli A; Raimondo D; Moretta P; Pignatiello S; Granata M; Seracchioli R; Zullo F; Insabato L
Pathol Res Pract; 2021 Jan; 217():153307. PubMed ID: 33316539
[TBL] [Abstract][Full Text] [Related]
35. Comparative immunohistochemical study of endometrioid and serous papillary carcinoma of endometrium.
Halperin R; Zehavi S; Habler L; Hadas E; Bukovsky I; Schneider D
Eur J Gynaecol Oncol; 2001; 22(2):122-6. PubMed ID: 11446475
[TBL] [Abstract][Full Text] [Related]
36. Morphologic Reproducibility, Genotyping, and Immunohistochemical Profiling Do Not Support a Category of Seromucinous Carcinoma of the Ovary.
Rambau PF; McIntyre JB; Taylor J; Lee S; Ogilvie T; Sienko A; Morris D; Duggan MA; McCluggage WG; Köbel M
Am J Surg Pathol; 2017 May; 41(5):685-695. PubMed ID: 28125452
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of contemporary chemotherapy in stage IIIC endometrial cancer: a histologic dichotomy.
Bakkum-Gamez JN; Mariani A; Dowdy SC; Weaver AL; McGree ME; Martin JR; Keeney GL; Jatoi A; Gostout BS; Podratz KC
Gynecol Oncol; 2014 Mar; 132(3):578-84. PubMed ID: 24434057
[TBL] [Abstract][Full Text] [Related]
38. Limited clinical benefit from trastuzumab in recurrent endometrial cancer: two case reports.
Vandenput I; Vanden Bempt I; Leunen K; Neven P; Berteloot P; Moerman P; Vergote I; Amant F
Gynecol Obstet Invest; 2009; 67(1):46-8. PubMed ID: 18843183
[TBL] [Abstract][Full Text] [Related]
39. Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I-type II study from the GINECO group.
Heudel PE; Fabbro M; Roemer-Becuwe C; Kaminsky MC; Arnaud A; Joly F; Roche-Forestier S; Meunier J; Foa C; You B; Priou F; Tazi Y; Floquet A; Selle F; Berton-Rigaud D; Lesoin A; Kalbacher E; Lortholary A; Favier L; Treilleux I; Ray-Coquard I
Br J Cancer; 2017 Jan; 116(3):303-309. PubMed ID: 28072765
[TBL] [Abstract][Full Text] [Related]
40. SATB2 Is Superior to CDX2 in Distinguishing Signet Ring Cell Carcinoma of the Upper Gastrointestinal Tract and Lower Gastrointestinal Tract.
Ma C; Lowenthal BM; Pai RK
Am J Surg Pathol; 2018 Dec; 42(12):1715-1722. PubMed ID: 30212392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
